CD8A and melanoma: Furthermore, in a placebo-controlled clinical trial using NY-ESO-1 protein (cancer testis protein) with ISCOMATRIX adjuvant in early-stage melanoma patients [44], immunized patients exhibiting antibody, delayed-type hypersensitivity, and CD4+ and CD8+ T cell responses appeared to have superior clinical outcomes to those treated with placebo or protein alone.